Cybin Inc. (NYSEAMERICAN:CYBN – Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 81,682 shares traded hands during trading, a decline of 39% from the previous session’s volume of 134,133 shares.The stock last traded at $9.37 and had previously closed at $9.18.
Cybin Price Performance
The firm has a market cap of $3.91 billion, a P/E ratio of -43.71 and a beta of 0.50.
Cybin (NYSEAMERICAN:CYBN – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.01) EPS for the quarter. Analysts expect that Cybin Inc. will post -0.22 earnings per share for the current year.
Institutional Trading of Cybin
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Recommended Stories
- Five stocks we like better than Cybin
- 3 Best Fintech Stocks for a Portfolio Boost
- The Average 401k Balance by Age Explained
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Most Volatile Stocks, What Investors Need to Know
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.